ImmunityBio, Inc. SEC filings IBRX
ImmunityBio, Inc. has 554 filings in SEC EDGAR's recent list, going back to Apr 29, 2005. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 4, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 9, 2026 |
| DEF 14C | Information statement | Oct 20, 2025 | Oct 20, 2025 |
| PRE 14C | Filing | Oct 8, 2025 | Oct 8, 2025 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 18, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 11, 2024 |
| DEF 14C | Information statement | Sep 28, 2023 | Sep 28, 2023 |
| PRE 14C | Filing | Sep 18, 2023 | Sep 15, 2023 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 14, 2022 |
| DEF 14C | Information statement | Jan 11, 2022 | Jan 11, 2022 |
| PRE 14C | Filing | Dec 30, 2021 | Dec 29, 2021 |
| DEF 14A | Proxy statement | Apr 29, 2021 | Jun 10, 2021 |
| DEFM14A | Filing | Feb 2, 2021 | — |
| DEF 14A | Proxy statement | Apr 24, 2020 | Jun 10, 2020 |
| DEF 14A | Proxy statement | Apr 26, 2019 | Jun 6, 2019 |
| DEF 14A | Proxy statement | Apr 24, 2018 | Jun 7, 2018 |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 9, 2017 |
| DEF 14A | Proxy statement | Apr 27, 2016 | Jun 15, 2016 |
Showing 23 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1326110
- Former names
- NantKwest, Inc. (until Mar 8, 2021); Conkwest, Inc. (until Jul 13, 2015); ZelleRx Corp (until Oct 9, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.